

May 11, 2017
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President and Chief Executive Officer
(Securities Code: 4582)

**Temporary Suspension of New Patient Enrollment in the Domestic Phase 3 Clinical Trial
of the Patient-controlled Pain Management Drug “SyB P-1501”**

TOKYO, Japan, May 11, 2017 -- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, "Symbio") announced today its decision on a temporary suspension of new patient enrollment in the domestic Phase 3 clinical trial of “SyB P-1501,” a drug for patient-controlled, short-term management of acute postoperative pain during hospitalization (“the Product”), which began in June 2016.

The Medicines Company (Headquarters: New Jersey, U.S., "MDCO") is the licensor of the Product (through its subsidiary, Incline Therapeutics, Inc.). MDCO filed a Form 10-Q with the U.S. Securities and Exchange Commission on May 5, 2017, in which it stated that MDCO intends to seek opportunities to partner or divest its business relating to the Product, and that if an acceptable transaction cannot be completed during the second quarter of 2017, MDCO may elect to discontinue commercialization of the Product.

Enrollment in the domestic clinical trial has progressed since achievement of the first patient enrollment in November 2016. The Form-10-Q filing by MDCO followed an April 21, 2017 conversation between MDCO and Symbio, which caused Symbio to become concerned as to the continuity of MDCO’s business regarding the Product, and hence on the same day decided to suspend temporarily new patient enrollment in the best interest of patients. Accordingly, Symbio reported the temporary suspension of the trial to the clinical trial sites and The Pharmaceuticals and Medical Devices Agency.

Symbio will continue the temporary suspension of the trial, pending further statements from MDCO as to the commercialization of the Product, and will comply with relevant timely disclosure requirements.

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited was established in March 2005 by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen Japan. In May 2016 the Company incorporated its wholly-owned subsidiary in the U.S., called SymBio Pharma USA, Inc. (Headquarters: Menlo Park, California, President: Mr. Fuminori Yoshida). The Company's underlying corporate mission is to “deliver hope to patients in need” as it aspires to be a leading global specialty biopharmaceutical company dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.